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Background: The Consortium of Hospitals Advancing Research on Tobacco (CHART) is a network of six projects
and a research coordinating unit funded by the National Heart, Lung, and Blood Institute, the National Cancer
Institute, the National Institute on Drug Abuse, and the National Institutes of Health (NIH) Office of Behavioral and
Social Science Research. The CHART projects will assess the effectiveness and cost-effectiveness of smoking
cessation interventions initiated during hospitalization and continued post-discharge.
Methods/design: Along with a seventh project funded previously under the NIH Challenge grants, the CHART
projects will assess smoking cessation strategies delivered to approximately 10,000 hospitalized smokers across a
geographically diverse group of nearly 20 private, public, academic, and community hospitals. The CHART research
coordinating unit at Kaiser Permanente Center for Health Research provides organizational and data coordination
support, facilitating the development of common measures for combining data from multiple CHART projects.
Discussion: The targeted enrollment in CHART, if achieved, will represent the largest, most diverse pooled dataset
of hospitalized smokers receiving smoking cessation assistance, and is designed to contribute to the dissemination
and implementation of smoking cessation interventions provided by hospital systems.
Keywords: Hospitals, Smoking cessation, Tobacco controlBackground
Hospitalization provides numerous advantages as a set-
ting for smoking cessation interventions. Many hospita-
lized smokers are admitted due to a smoking-related
illness, providing a serious and salient motivational
prompt for quitting smoking. During hospitalization,
patients have access to a range of health care staff poten-
tially able to provide various smoking cessation services.
Hospitalization also provides a compulsory period of ab-
stinence, particularly in hospitals with well enforced
smoke-free campus policies, that provides patients with
a “head start” in the quitting process.
By leveraging these advantages, a number of studies
have shown that behavioral and pharmacologic smoking
cessation interventions provided to hospitalized smokers
are efficacious in improving cessation rates. In a recent
meta-analysis Rigotti and colleagues [1] found that* Correspondence: wiriley@mail.nih.gov
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reproduction in any medium, provided the orsmoking cessation interventions initiated during
hospitalization and continued post-discharge for at least
1 month increase the odds of long-term cessation by
65%. A recent meta-analysis with Monte Carlo modeling
of cost-effectiveness estimated that smoking cessation
counseling with follow-up contact for all US smokers
hospitalized with acute myocardial infarction (AMI)
would cost $540 per quitter to implement and would
prevent 1,380 nonfatal AMIs and 7,860 deaths [2]. Given
the clear positive impacts of smoking cessation services
provided during and following hospitalization, the Joint
Commission recently updated its performance measures
to include inpatient and post-discharge provision of
smoking cessation counseling and medications to all
patients effective 1 January 2012 [3].
The National Heart, Lung, and Blood Institute
(NHLBI) convened a workgroup in 2008 to evaluate
the state of the science in this area and to consider
directions for future research. They considered various
types of smoking cessation services for hospitalized
patients and the barriers to their implementation [4].
This workgroup noted the need for effectiveness andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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interventions that could be easily adopted and inte-
grated into hospital systems. Based on these workgroup
findings, the NHLBI, along with the National Cancer In-
stitute (NCI), National Institute on Drug Abuse (NIDA)
and the National Institutes of Health (NIH) Office of
Behavioral and Social Science Research (OBSSR),
released a request for applications (RFA) on “Effective-
ness Research on Smoking Cessation in Hospitalized
Patients (U01)” (RFA-HL-10-020 and RFA-HL-10-025).
The purpose was to encourage research to evaluate the
translation of efficacious smoking cessation strategies
initiated during hospitalization and continued post-
discharge into effective programs that can be widely
implemented in routine clinical practice, and assess the
cost-effectiveness of these interventions.
Methods/design
Overview of the CHART collaborative group
From the RFAs, six cooperative agreements and a re-
search coordinating unit (RCU) were funded. In
addition, a previously funded NIH Challenge grant (RC1
HL 099668) was invited to join the CHART network.
Table 1 lists the grantee institutions, the hospitals par-
ticipating in the consortium, and a brief description of
the interventions being compared to usual care in these
seven projects. The CHART projects include hospitals
from every region of the US, representing academic
medical centers, community public hospitals, and private
hospitals. Combined enrollment in the CHART studiesTable 1 Consortium of Hospitals Advancing Research on Toba
Grant PI Institution Hospitals (numbe
U01 DA 031515 Bailey University of Alabama
Birmingham
UAB University Hos
U01 HL 105218 Duffy University of Michigan Trinity Health Syste
Community Hospit












U01 HL 105229 Sherman New York University Bellevue, Manhatta




and La Jolla hospit
IVR, interactive voice response; NRT, nicotine replacement therapy; PI, Principal Inveis expected to include approximately 10,000 hospitalized
smokers.
The interventions evaluated by these projects are
diverse. While some intervene primarily during
hospitalization (for example, Duffy and Richter), others
intervene primarily during post-discharge follow-up
(for example, Zhu and Bailey). Post-discharge cessation
counseling is provided via conventional telephone
counseling (for example, Zhu, Sherman and Richter) as
well as by more innovative methods such as internet
websites (for example, Bailey) and interactive voice re-
sponse (for example, Fellows and Rigotti). Some pro-
vide cessation medications for a specified period of
time post-discharge to all for whom they are indicated
while other interventions do not provide cessation
medications but may include efforts to encourage
attending physicians to include these medications in
their discharge orders. Most of the projects are stan-
dard two-arm randomized clinical trials comparing ac-
tive intervention to usual care; however, the Zhu
protocol uses a factorial design to test the effects of
nicotine replacement and telephone counseling alone
and in combination, and the Duffy protocol randomly
assigns hospitals to receive nurse training in smoking
cessation interventions.
Research coordinating unit and consortium governance
structure
Although each project tests different interventions in dif-
ferent hospital settings, the RFA specified a cooperativecco (CHART) projects
r) Total N intervention description
pital (one) 1488 Post-discharge interactive
web-based program that
offers tailored information,
e-group support, and text messages
m
als (six)
2350 Nurse-administered Tobacco Tactics
intervention during hospitalization with




900 Post-discharge IVR-supported assisted




994 Warm handoff – Assist patient in making
initial quitline contact while in hospital
eral 330 Post-discharge IVR assisted telephone
counseling x 3 mos. plus a 30 day supply
of smoking cessation medication
n VA (two) 3100 Post-discharge multi-session telephone





1600 2 x 2 factorial design comparing
post-discharge NRT, proactive telephone
counseling, and combined
stigator.
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used to address questions beyond the scope of any indi-
vidual project. To facilitate project coordination, a com-
panion RFA solicited for a RCU to organize and support
network functions, including planning meetings, sup-
porting communication and document sharing through-
out the consortium, supporting communications with
the consortium’s Data and Safety Monitoring Board
(DSMB), and facilitating the development and imple-
mentation of a common set of baseline and follow-up
measures to be used by the CHART projects. The RCU
was awarded to Kaiser Permanente Center for Health
Research in Portland, Oregon (U01 HL 105233, Principal
Investigator (PI ) Victor Stevens).
The CHART organizational structure, which was spe-
cified by the RFA, closely matched the structure used in
the Obesity Prevention at the Worksite consortium [5].
The RCU PI currently serves as chair of the CHART
Steering Committee (SC). The voting members of the
SC include the PIs of each research project and the lead
project scientists of the three primary funding institu-
tions (NHLBI, NCI, and NIDA). The SC meetings are
open to other project investigators and staff. The SC
meets monthly by conference call and at least twice a
year in person. The SC sets all policies for the consor-
tium, creates sub-committees as needed, and is respon-
sible for resolving any issues that may arise within the
consortium.
The CHART SC created the following subcommittees:
1) Design and Analysis subcommittee responsible initially
for considering and recommending common inclusion/
exclusion criteria and common baseline and outcome
measures across projects; 2) Cost-Effectiveness subcom-
mittee within the Design and Analysis subcommittee re-
sponsible for considering and recommending common
cost-effectiveness data collection procedures across pro-
jects; 3) Recruitment and Retention subcommittee re-
sponsible initially for determining and recommending
common procedures for monitoring and reporting of the
recruitment and enrollment process; 4) Safety subcom-
mittee responsible initially for determining and recom-
mending common procedures for adverse event and
serious adverse event responses and reporting proce-
dures; and 5) Publications subcommittee responsible ini-
tially for considering and recommending collaborative
publications of the CHART network.
Consortium communications are coordinated by the
RCU. The RCU established and maintains a password-
protected communications website to facilitate com-
munications and document sharing across the CHART
projects. The RCU also coordinates the biannual in-
person meetings and the monthly teleconference meet-
ings of the CHART SC as well as the meetings of the
various subcommittees.CHART DSMB
The CHART DSMB, constituted by the NHLBI Director,
consists of six members who meet twice a year and are
charged with advising the NHLBI regarding study design
and statistical issues, data control, participant safety and
adverse events, and the operational aspects of the trials.
The CHART DSMB follows NHLBI DSMB guidelines
[6]. Following an open session that includes project PIs
and other study staff as required, DSMB members along
with the NHLBI executive secretary and biostatisticians
from each project meet in closed session to review
blinded materials, then the biostatisticians are excused
and the DSMB meets in executive session to discuss
issues and generate recommendations. The CHART
DSMB convened initially on 5 to 6 April 2011 to review
and approve the six protocols formally in the CHART
network.Common baseline and inclusion/exclusion criteria
To facilitate pooled data analyses, the CHART SC con-
sidered three tiers of measures:
Tier 1: Variables that all CHART projects will measure
using the same procedures;
Tier 2: Variables that each CHART project has the
option to measure, but those opting to measure these
variables will do so using the same procedures;
Tier 3: Variables unique to each CHART project.
Common baseline inclusion/exclusion, patient-
reported, and medical record Tier 1 measures approved
by the CHART SC are shown in Table 2. In the process
of developing these common baseline measures, the
CHART SC and the Design and Analysis subcommittee
balanced the numerous possible predictor or moderator
hypotheses that could be considered with the response
burden of completing these measures, especially for
often acutely ill hospitalized patients. Additionally, a
core aim of the CHART projects is to produce results
that can be implemented easily in hospital systems, and
algorithms involving the assessment of multiple modera-
tors to personalize treatment introduces complexity that
may hinder implementation. Therefore, only 13 baseline
patient reported variables (three for inclusion/exclusion
purposes) and 10 medical record variables are included
in Tier 1. For Tier 2, those projects measuring nicotine
dependence, alcohol use, depression, or quality of life
agreed to use the Heavy Smoking Index [7], Audit-C [8],
PHQ-2 [9], and the EQ-5D-5 L [10], respectively.
Projects can use longer forms of these measures (for
example, FTND instead of the Heavy Smoking Index,
PHQ-9 instead of PHQ-2), but the shorter forms con-
stitute the shared Tier 2 dataset.
Table 2 Tier 1 common baseline measures of the




1 Length of stay (hours, calculated
from admission and discharge
date/time)
2 Height (cm or in)
3 Weight (kg or lbs)
4 Insurance (public, private, none)
5 Primary and secondary discharge
diagnoses (ICD-9)
6 Diagnostic related groups
7 Procedure codes
8 Admission through emergency
room (yes, no)
9 Hospital service at admission
10 Discharge plan (home, skilled
nursing, rehab)
Eligibility criteria measures
1 Patient age (via medical record
or patient report)
2 Did you smoke a cigarette (even
one puff) in the past 30 days? (yes, no)
3 What is your plan about smoking
after you leave the hospital? (I plan to
quit when I leave the hospital, I plan
to try to quit when I leave the hospital,
I don’t know if I’m going to quit,
I do not plan to quit)
Baseline Patient Report
1 Are you of Hispanic, Latino, or
Spanish origin (yes, no)
2 What is your race? (standard NIH
response options)
3 What is your sex? (male, female, other)
4 What is the highest level of education
that you havecompleted?
(< high school, high school, general
equivalency exam, some college,
4 year college graduate or higher)
5 What is your marital status?
(married/domestic partner, separated,
divorced, widowed, never married)
6 In the past 30 days, on how many
days did you smoke? (1 to 30)
7 On the days you smoked, how many
cigarettes on average did you smoke?
8 Did you use any other tobacco
product besides cigarettes in the
past 30 days?
9 How confident are you that you will
be able to quit/stay quit once you are
discharged from the hospital (5 point
scale from “not at all confident”
to “very confident”)
Table 2 Tier 1 common baseline measures of the
Consortium of Hospitals Advancing Research on Tobacco
(CHART) network (Continued)
10 Does anyone in your household
smoke (other than you)?
(yes/no/live alone)
ER, emergency room; HS, high school; GED, general equivalency exam.
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oped a cost-effectiveness analysis plan that allows the
CHART network to pool data on the cost of interven-
tion delivery, health care utilization of participants during
the 1 year post-discharge, and estimates of quality-
adjusted life years in those projects administering health
utility measures. All projects are estimating intervention
costs for cost-effectiveness analyses from a health system
(hospital, insurer) perspective using Tier 1 measures and
procedures for estimating total cost, cost per patient,
and cost per quit for each intervention arm, and incre-
mental cost-effectiveness ratios between intervention
arms. Health care utilization and/or expenditures, pri-
marily focused on inpatient, outpatient, and emergency
department encounters, will be assessed by all projects
via participant report at 6 and 12 months, and costs for
utilization will be estimated from diagnostic-related,
group-specific Medicare cost weights and other national
cost estimates. Projects involving closed systems (for
example, HMOs, VA) will also be able to extract actual
health care utilization and costs from medical and
claims records, and these data will be used for com-
parison and for cost estimate and utilization adjust-
ments as appropriate.
For inclusion/exclusion criteria, the CHART SC
agreed that all projects will define a smoker as any pa-
tient who reports having smoked cigarettes, even one
puff, in the 30 days prior to hospital admission. This cri-
terion is consistent with most cessation studies of hospi-
talized smokers [1] and, although it may include some
light or intermittent smokers, this criterion insures the
inclusion of regular smokers who have not smoked re-
cently due to illness.
For exclusion criteria, the CHART projects are
designed to be as inclusive as possible, excluding primar-
ily those patients who are not able to grant informed
consent and complete the screening questions due to ill-
ness severity, cognitive impairment, and/or illness-
related communication difficulties. Some of the CHART
projects exclude specific hospital services or units (for
example, psychiatric, neurological, and intensive care)
while others do not. The interventions provided by some
of the projects necessitated additional exclusion criteria
(for example, minimal smoking rates for nicotine re-
placement therapy (NRT) , and access to the internet
post-discharge to access the web-based intervention),
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interested in quitting or staying quit while others include
all smokers. To facilitate combining data across projects
with different exclusion criteria, the CHART projects will
assess these exclusion criteria whether or not the individ-
ual project excludes on that basis, thus allowing the
CHART group to analyze pooled data based on the most
stringent exclusion criteria across all projects, and to per-
form sensitivity analyses on the effects of including versus
excluding patient groups excluded by some projects.
To facilitate combining common measures across pro-
jects, the RCU will develop variable and value labels to
be used by all projects for the Tier 1 and 2 variables.
Local projects may use any local data system that will
allow production of data sharing files using one of the
following formats: SAS, SPSS, or STATA. To ensure
consistency, the RCU staff will review plans for collect-
ing common measures, data entry procedures, and data
storage formats for each project before the initiation of
data collection. The RCU also will create a secure data
transfer website for common measures that will allow
authorized users to post data and retrieve files.
Common outcome measures
The CHART projects proposed a range of cessation out-
comes, including continuous, prolonged, and 7- and 30-
day point prevalence abstinence at 6 and 12 months as
well as survival analyses. For a common primary out-
come, the CHART SC agreed to 30-day point prevalence
at 6 months following hospital discharge. The 6-month
follow-up is expected to have less missing data than 12
months, conforms to the minimal recommended follow-
up for smoking cessation trials [11,12], and is consistent
with recent data showing that the relapse curve of smo-
kers hospitalized for acute coronary syndrome becomes
asymptotic within 6 months of admission [13]. The 30-
day point prevalence criterion was selected as the pri-
mary cessation outcome in part for consistency with the
inclusion criteria (that is, participants are defined as a
smoker if they smoked within the past 30 days, whether
in the 30 days prior to hospitalization or within 30 days
of the follow-up assessment), and other studies of hospi-
talized smokers (for example, PREMIER [14]) also have
defined smoking cessation as not smoking within 30
days of the 6 month follow-up.
Although prolonged abstinence is recommended as
the primary outcome for smoking cessation studies
[11,12], its definition and meaning in the context of
interventions for hospitalized smokers is complex. One
rationale for prolonged abstinence is the improved confi-
dence that cessation is the result of the intervention
given their temporal proximity. The duration of the vari-
ous CHART interventions, however, range from 4 to 26
weeks post-discharge, making it difficult to define acommon period during which most would attempt to
quit, or a common grace period in which slips imme-
diately following a quit attempt might occur. Those
ready to quit are likely to attempt to continue the ab-
stinence initiated during hospitalization and may slip
for a short period after discharge but otherwise remain
abstinent. For this group, prolonged abstinence with a
2- to 4-week grace period post-discharge is reasonable.
Some of the CHART studies, however, include all smo-
kers including those with little to no interest in quit-
ting after discharge, some of whom may later quit as a
result of the continued intervention provided, but
these would be defined as failures based on the pro-
longed abstinence definition above. Given the varying
effects of these different interventions on heteroge-
neous subgroups of hospitalized smokers, the CHART
SC decided that 30-day point prevalence, not pro-
longed abstinence, should be the common primary
outcome. Via pooled analyses, the CHART network
will be able to compare continuous, prolonged, 30-
and 7-day point prevalence abstinence across a large
and diverse sample of hospitalized patients and be able
to better describe the relationship between these vari-
ous definitions of cessation outcome.
The CHART SC considered a range of abstinence val-
idation procedures for the 7-day point prevalence out-
come at 6 months including mailed and in-person saliva
sample collection with cotinine determined via standard
laboratory procedures or via test strips, in-person
expired carbon monoxide for those reporting continued
NRT use, and even proxy report when biochemical vali-
dations could not be obtained. Regardless of procedure,
the CHART SC remained concerned that the rates of
validation completion would be less than optimal and
result in a substantial percentage of abstinent partici-
pants misclassified as smokers due to failure to obtain
biochemical validation samples. A previous study of hos-
pitalized smokers illustrates the competing concerns of
missing biochemical samples in those reporting absti-
nence and misclassifying smokers as abstinent if bio-
chemical verification is not obtained. Hennrikus and
colleagues [15] were able to obtain saliva samples from
71.7% of hospitalized smokers who reported abstinence
at 12 months, and 19.9% of these samples disconfirmed
self-reported abstinence. Across cessation studies, self-
report tends to overestimate abstinence compared to
biochemically determined abstinence, with an average
sensitivity of 86% compared to saliva cotinine and con-
siderable variability in sensitivity between studies [16].
The Society for Research on Nicotine and Tobacco bio-
chemical verification guidelines indicate that “in large-
population, low-intensity intervention trials, biochemical
validation is neither feasible nor necessary”, but also in-
dicate that medical patients with smoking-related
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chemical verification is recommended [17].
To address the biochemical validation question, the
CHART SC decided to rely on self-reported abstinence
as the primary measure and conduct a substudy in
which a sample of abstinent-reporting participants will
receive intensive efforts to obtain biochemical validation
at 6 months. The goal of these intensive efforts (for ex-
ample, considerable incentives, additional staff effort) is
to obtain the highest possible rate of completed bio-
chemical validations on this sample of those reporting
abstinence. These data will be used by the CHART net-
work to estimate the validated abstinence rates across
the full sample and by intervention and control condi-
tions, and provide the smoking cessation research com-
munity with data on the sensitivity of self-report in this
large sample of hospitalized smokers.
Participating projects will identify participants report-
ing 7-day point-prevalence abstinence at 6 months. If
not on nicotine replacement, these participants will re-
ceive materials for collecting a salivary sample to return
via mail. Up to five phone or mail reminders will be per-
formed to obtain the sample, and an in-home visit will
be offered to those within an hours commute of study
staff if the sample is not obtained by the fourth phone or
mail contact. These samples will be frozen and batched
shipped to Salimetrics (State College, PA, USA) for anal-
ysis using enzyme immunoassay. A cut-point of 15 ng/ml
will be used to differentiate smokers and non-smokers
but sensitivity analyses will be performed with lower
recommended cut-points as well. Based on initial power
analyses, 442 participants will provide 80% power to de-
tect a 15% difference in misreporting between interven-
tion and control groups, and over 95% power to estimate
the overall misreporting rate to within 5%. For the smaller
CHART studies, the sample to contribute to this substudy
will approximate the full sample of 7-day point prevalence
abstinent participants at 6 months, so many of these
studies plan on conducting these procedures for all 7-day
abstinent participants.
CHART intervention and comparison conditions
As noted previously, the CHART projects vary consider-
ably in the components, dose, timing, and mode of de-
livery of the smoking cessation interventions being
evaluated, and it was not the intent of the initiative that
the interventions should be harmonized. Although the
active intervention conditions are not harmonized across
projects, the CHART network agreed that the compari-
son condition should be usual care across all projects. In
addition to improving the likelihood of finding a differ-
ence between the active and control conditions, requir-
ing usual care as the comparison condition for all
studies provides the opportunity to pool data from theusual care conditions across hospitals to document and
study the effects of usual care smoking cessation deliv-
ered by a variety of hospital systems. The CHART net-
work anticipates that usual care will differ substantially,
not only between hospitals but also over time within
hospitals, particularly as a result of new Joint Commis-
sion requirements on the provision of smoking cessa-
tion services in hospital settings. Although this
heterogeneity between and within usual care will limit
efforts for pooled comparisons of usual care to the vari-
ous interventions, it will provide a detailed documenta-
tion of usual care for smoking cessation in a range of
hospital settings and allow for analyses of those compo-
nents of usual care that may be associated with better
outcomes.Discussion and conclusion
The CHART network is a consortium of an RCU, six
U01s and an associated RC1 project whose primary aim
is to study the effectiveness and cost-effectiveness of
smoking cessation interventions initiated during
hospitalization and continued post-discharge. Over the
4-year project, the NIH (NHLBI, NCI, NIDA, and
OBSSR) plans to invest over $20 million in this network
of studies. The network will study cessation interven-
tions in nearly 20 hospitals that represent a diverse array
of patient demographics and health care resources. The
CHART network has developed a set of common out-
comes, baseline measures, and inclusion/exclusion cri-
teria to facilitate pooled data analysis of approximately
10,000 patients expected to participate in the studies.
CHART and other similar consortia represent a mid-
dle ground between independent studies and multisite
standard protocols. The CHART projects are technically
independent of one another and have “site rights” to de-
cide what is best for their study. The study investiga-
tors, however, have also agreed to work together to
build consensus on common measures, inclusion cri-
teria, and other aspects of study protocol to facilitate
data sharing and pooling. Limitations of this approach
include the inability to directly compare conditions
across projects since each project has different interven-
tion and comparison conditions. This necessitates the
coding of intervention components and associating
these components with outcomes after controlling for
project-specific and participant-specific factors to esti-
mate the effects of these various treatment components.
The strength of this type of consortia, however, is the
ability to plan for harmonizing and pooling common
data elements, providing a shared dataset of sufficient
size to evaluate possible moderators and mediators of
treatment effect that no independent study alone could
perform.
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for dissemination. The projects are evaluating interven-
tions that can be easily implemented in hospital settings,
and dissemination and implementation issues have been
an important consideration in all CHART network deci-
sions. When completed, the CHART studies should pro-
vide hospital systems with a number of effective
smoking cessation interventions, at least one of which
can serve as the basis for a smoking cessation interven-
tion that fits with the resources and infrastructure of
their hospital system. Pooled data on the relationship of
outcomes to various intervention components, both for
the intervention and usual care conditions, should pro-
vide additional guidance on the relative importance of
various intervention components for maximizing cessa-
tion outcomes. These pooled analyses should also give
hospital systems with limited resources guidance on
which patient groups are more likely to benefit from
these interventions and possible stepped interventions
based on intervention intensity needed to support cessa-
tion. The knowledge gained from the CHART initiative
should have a significant impact on the delivery of
smoking cessation interventions in hospital settings.
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